METHOD OF TREATING GLAUCOMA

Abstract

Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the present invention and the advantages thereof may be acquired by referring to the following description, taken in conjunction with the accompanying drawing in which like reference numbers indicate like features and wherein:

FIG. 1 is a bar graph showing the effects of Compound 1 on the survival of cultured adult rat retinal ganglion cells (RGCs).

Claims

1. A method for the treatment of ocular hypertension or glaucoma, which comprises administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3.

2. The method of claim 1, wherein the compound is selected from the group consisting of:

3. The method of claim 2, wherein the compound is selected from the group consisting of:

4. The method of claim 1, wherein the compound is administered in an implant.

5. The method of claim 1, wherein the compound is administered as an intraocular injection.

6. The method of claim 1 wherein the compound is administered topically to the eye in a composition comprising a pharmaceutically acceptable carrier.

7. The method of claim 6 wherein the pharmaceutically effective amount of the compound in the composition is from 0.001 to 2% (w/v).

8. The method of claim 7 wherein the pharmaceutically effective amount is from 0.01 to 1% (w/v).

9. The method of claim 6, wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; gelling agents, vehicles, water, penetration enhancers, and viscosity building agents.

10. The method of claim 1 wherein said administering further comprises administering said one or more compounds together with or separate from at least one glaucoma treatment agent selected from the group consisting of: β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, α2 agonists, miotics, rho kinase inhibitors and neuroprotectants.